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cortical inhibition over the left hemisphere. Apart from an 
enhanced intracortical facilitation, FE-SZ patients did not dif-
fer compared to ADHD patients in the main outcome mea-
sures. Both patient groups presented a dysfunctional hemi-
spheric pattern of cortical inhibition and facilitation in
comparison with HC.  Conclusion: The results of this study 
indicate a pattern of cortical disinhibition and abnormal 
hemispheric balance of intracortical excitability networks in 
two different psychiatric diseases. These effects might be as-
sociated with an imbalance in GABAergic and dopaminergic 
transmission and might provide evidence for a common 
pathophysiological pathway of both diseases. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Attention deficit hyperactivity disorder (ADHD) and 
schizophrenia are both heterogeneous disorders sharing 
a psychopathological profile of attention deficits and dif-
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 Abstract 
 Background: First-episode schizophrenia (FE-SZ) and atten-
tion deficit hyperactivity disorder (ADHD) are both neuro-
psychiatric disorders associated with an impaired dopami-
nergic transmission. Though displaying different clinical 
phenotypes, a common pathophysiological pathway is dis-
cussed controversially. Several studies using transcranial 
magnetic stimulation (TMS) revealed abnormalities in hu-
man motor cortex excitability in both schizophrenia and 
ADHD patients. Studies on cortical excitability comparing 
these two diseases directly are lacking.  Method: In this
study, a total of 94 subjects were analyzed. Twenty-five FE-SZ 
patients were directly compared with 28 ADHD patients and 
41 healthy controls (HC). We investigated cortical excitability 
(inhibitory and facilitatory networks) with single- and paired-
pulse TMS to the left and right motor cortex.  Results: Com-
pared to HC, FE-SZ/ADHD patients displayed an impaired 
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ficulties in social interaction. However, very clear distin-
guishing features between these diseases are delusions, 
hallucinations and negative symptoms as a clinical man-
ifestation in schizophrenia patients  [1] . There is comor-
bidity between these diseases and retrospective studies of 
individuals with schizophrenia have shown a history of 
premorbid or concomitant ADHD  [2] .
 With regard to the pathophysiology, both conditions 
are associated with a dysfunctional dopaminergic trans-
mission of the limbic-frontal network and other mid-
brain structures  [3, 4] . An enhanced dopaminergic trans-
mission in mesolimbic structures is associated with pos-
itive symptoms, whereas a dopaminergic underactivity
in these brain structures has been linked to negative 
symptoms and cognitive dysfunction in schizophrenia 
patients. In ADHD, the pathophysiological role of the 
 dopamine system remains elusive. Both, high midbrain 
dopamine activity or reduced dopamine activity are dis-
cussed to be involved in the appearance of ADHD symp-
toms, and the discussion about hypo- or hyperdopami-
nergic transmission imbalance remains contradictory  [4, 
5] . In some studies, a dopaminergic hyperfunction in the 
mesolimbic structures was correlated with  hyperactivity 
and impulsivity and a dopaminergic hypofunction was 
found to underlie different cognitive symptoms  [3, 4, 
6–8] . Apart from dopamine, other neurotransmitter sys-
tems, especially GABAergic interneurons, are involved in 
the pathophysiology of these diseases  [9, 10] .
 Using paired-pulse transcranial magnetic stimulation 
(TMS), a reduced cortical inhibition as another common 
pathophysiological state was found in both diseases  [11, 
12] . Paired-pulse TMS offers the possibility to investigate 
different mechanisms of cortical inhibition (short-inter-
val intracortical inhibition, SICI) and of cortical facilita-
tion (intracortical facilitation, ICF) in the human brain 
 [13] . SICI is discussed to be mediated by GABAergic in-
terneurons via GABA A receptors and ICF might result 
from primarily glutamatergic neurotransmission  [14] . 
Furthermore, dopaminergic neurotransmission has an 
impact on SICI and ICF, because dopamine agonists lead 
to an enhancement of SICI and ICF and dopamine an-
tagonists reduce SICI and ICF in healthy subjects  [14] . 
The contralateral silent period (CSP), a single-pulse TMS 
measure, is at least in part the result of GABA B -mediated 
inhibitory mechanisms  [15, 16] .
 In schizophrenia patients, several TMS studies re-
vealed abnormalities in motor-cortical excitability which 
have been linked to GABAergic and dopaminergic dys-
function  [17–20] . Our research group has recently dem-
onstrated a reduced SICI and a prolonged CSP in first-
episode schizophrenia (FE-SZ). We hypothesized that re-
duced SICI points towards a GABA A deficit and the 
prolonged CSP may reflect compensatory increased 
GABA B transmission induced by hyperactivity of the do-
paminergic system  [11, 21] .
 Studies with child and adult ADHD patients displayed 
controversial results. Three different studies found abnor-
mal SICI and ICF in children with ADHD, which normal-
ized after administration of a psychostimulant  [22–24] . 
Furthermore, a reduced duration of the CSP and the ipsi-
lateral silent period, a measure of interhemispheric con-
nectivity, is a common finding in children with ADHD 
 [23, 24] . In adults with ADHD, two studies revealed a re-
duced SICI  [12, 25] and in another study the reduced SICI 
did not reach statistical significance  [26] . Methodological 
differences in measuring and analyzing cortical excitabil-
ity in adults with ADHD might be related to the negative 
finding of the latter study. The shift of ADHD symptoms 
during lifetime might be accompanied by adaptations in 
motor cortex excitability in some ADHD phenotypes. 
Furthermore, the higher variability of motor evoked po-
tentials (MEPs) in ADHD might be the reason for the 
weak statistical significances of differences in cortical ex-
citability between some ADHD adults and healthy con-
trols (HC)  [26] . As shown for ADHD in childhood, one 
study found a shortened ipsilateral silent period in adult 
ADHD, but there were no differences in CSP  [27] .
 The present study was designed to directly compare 
measures of cortical excitability between ADHD and FE-
SZ. To shed more light on the impact of cortical excitabil-
ity on the underlying pathophysiology, 25 FE-SZ patients 
with minimal exposure to antipsychotics were compared 
with 28 adult ADHD patients with no history of psychot-
ic or other axis I or II disorders and 41 HC. Therefore, 
previously and independently published samples (see 
Materials and Methods) were merged and newly ana-
lyzed regarding excitability differences between schizo-
phrenia and ADHD patients. TMS over both hemispheres 
was used to test parameters of cortical excitability and 
functional hemispheric balance (SICI, ICF, CSP and mo-
tor thresholds).
 Our aim was to focus on TMS measures on transmis-
sion mechanisms related to GABA A , GABA B and gluta-
matergic systems in order to test the hypotheses of com-
mon pathophysiological motor networks in schizophre-
nia and ADHD. From the background outlined above, we 
hypothesized that schizophrenia patients would show the 
most pronounced abnormality in excitability that is less 
evident in ADHD. Another aim was to investigate func-
tional hemispheric symmetry/connectivity using mea-
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sures of cortical excitability. Our hypothesis was that 
there is an imbalance in both disorders and schizophre-
nia patients would show the most pronounced deficit.
 Materials and Methods 
 Subjects 
 The study sample consisted of 94 subjects. Twenty-eight pa-
tients with ADHD and 25 patients with FE-SZ (all paranoid sub-
type) from the same geographical area were recruited from inpa-
tient and outpatient units and were compared with 41 healthy 
subjects. Parts of the sample have previously been published in-
dependently  [11, 21, 25] , but this study provides new data on direct 
comparison of disorders, CSP in ADHD and late-ICF in FE-SZ. 
Subjects with a history of dementia, neurological illnesses and 
severe brain injuries were excluded from the study. Only right-
handed subjects according to a standardized test of hand prefer-
ence  [28] were analyzed for this study.
 A clinical psychiatrist, blinded to the aims of the study, and a 
member of the study group (T.W. or M.S.) made a consensus diag-
nosis according to the German version of the Structured Clinical 
Interview for DSM-IV  [29] . Each subject underwent an assessment 
of disease severity (Clinical Global Impressions)  [30] and an assess-
ment of social functioning (Global Assessment of Functioning) 
 [31] . In schizophrenia patients, an assessment of psychopathology 
(Positive and Negative Syndrome Scale)  [32] , the duration of ill-
ness, counted from the beginning of initial prodromal symptoms, 
and the duration of psychosis, counted from the onset of diagnos-
tic/characteristic positive symptoms, were evaluated according to 
the foregoing publication  [11] . All schizophrenia patients were 
treated with second-generation antipsychotics, but at the time of 
TMS measurements, no patient had been treated longer than 6 
weeks continuously. We calculated chlorpromazine equivalents 
 [33] for the cumulative and daily doses of the different antipsychot-
ics to explore the influence of this medication on the study results.
 The ADHD patients (combined type) were diagnosed accord-
ing to the diagnostic criteria of DSM-IV (ADHD diagnostic 
checklist  [34] ), and had used no stimulant medication before. The 
Wender Utah Self-Rating Scale (short version)  [35] was used to 
assess childhood ADHD symptoms. Patients with a clinical diag-
nosis of ADHD were included in the study if the Wender Utah 
Self-Rating Scale (short version) score was at least 30, and if at least 
6 of 9 items of inattention and hyperactivity/impulsivity were 
present. As indicators of severity of symptoms, the ADHD self-
rating scale for adults according to DSM-IV  [34] was used (total 
score: 0–54; attention deficit and hyperactivity/impulsivity sub-
scores: each maximal 27). The Structured Clinical Interview for 
DSM-IV Axis I and II Disorders was used to exclude further axis 
I and II DSM categorical diagnoses.
 After a complete description of the study, written informed 
consent was obtained from each subject. The local ethics commit-
tee approved the protocol, which is in accordance with the Decla-
ration of Helsinki.
 TMS Procedure 
 As described previously  [11] , subjects were seated in a comfort-
able reclining chair with their arms supported passively. Electro-
myographic (EMG) recordings from the right and left first dorsal 
interosseous muscle (FDI) were made with surface electrodes. 
Raw signals were amplified, bandpass filtered (2 Hz to 10 kHz) 
and digitized using a commercial amplifier (Keypoint portable, 
Medtronic Co., Denmark). Each EMG recording was manually 
analyzed off-line. TMS was performed by using a MagPro  ! 100 
magnetic stimulator (Medtronic Co., Denmark) and focal TMS 
was applied to the hand area of the left and right motor cortex with 
a standard figure-of-eight magnetic coil. The optimal coil posi-
tion was defined as the stimulation site that produced the largest 
MEP at moderately suprathreshold stimulation intensities (i.e. in-
tensities that induce MEPs of about 0.5–1.5 mV) in the resting 
right and left FDI. The optimal position was marked to ensure 
that the coil was held in the correct position throughout the ex-
periment. The coil was held tangentially to the head, with the 
handle pointing backwards and in an angle of 45° lateral to the 
midline. This ensured that the induced current pointed forward 
and perpendicular to the central sulcus, which is optimal for pro-
ducing transsynaptic activation of corticospinal neurons. The 
resting motor threshold (RMT), expressed as a percentage of 
maximum stimulator output, was defined as the lowest intensity 
that produced an MEP of  1 50   V in 5 out of 10 trials in the relaxed 
FDI.
 In accordance with standard TMS publications, SICI and ICF 
were obtained  [13, 18] , setting the intensity of the conditioning 
stimulus at 80% of the RMT and the test stimulus at an intensity 
that produced MEPs averaging 0.5–1.5 mV in the resting FDI. 
SICI/ICF were measured with interstimulus intervals (ISIs) of 3, 
5, 7 and 15 ms, and we performed a minimum of 8 trials with each 
ISI and 10 trials with the test stimulus alone. The effect of the con-
ditioning stimulus on MEP amplitude of the test stimulus was 
determined as the ratio of the average amplitude of the condi-
tioned MEP to the average amplitude of the unconditioned test 
MEP.
 CSP duration was obtained in moderately tonically active FDI 
(25–30% of maximal contraction) by stimulating the contralat-
eral motor cortex with intensities of 120 and 140% of RMT. For 
each intensity, 8 trials were performed and the mean CSP dura-
tion calculated. The CSP duration was defined as the time from 
the MEP onset to the return of any voluntary EMG activity (ab-
solute CSP)  [36] .
 All measurements and clinical characterizations were per-
formed by an experienced investigator (FE-SZ: T.W.; ADHD: 
M.S.), controlled by another experienced investigator (FE-SZ: 
M.S.; ADHD: T.W.), and corrected for outliers and extreme val-
ues. The data analysis was performed by A.H., T.W., M.S. and one 
statistician (T.S.A.).
 Statistical Analyses 
 For statistical analyses, SPSS for Windows 17.0 was used. All 
tests were two-tailed. The level of significance was set at   = 0.05. 
Data are presented as mean  8 standard deviation unless other-
wise indicated. Kolmogorov-Smirnov tests were applied to test 
normal distribution and logarithmic transformation was used if 
normality assumption was violated (SICI and ICF). Independent 
factor was group (FE-SZ, ADHD, HC) and dependent variables 
were RMT, ISI (3, 5, 7, 15 ms) and CSP (intensities 120 and 140% 
of RMT) on both hemispheres. As initial analyses, Pearson cor-
relations between age and dependent variables were calculated 
and one-way ANOVA was performed to analyze if the factor gen-
der influenced the dependent variables. If a significant influence 
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of these intervening variables was found, the main analyses were 
adjusted for these variables.
 A repeated-measures multivariate analysis of variance (RM-
MANOVA) with the within-subject factor ‘side’ (left and right 
hemisphere) and the between-subject factor ‘group’ (HC, ADHD, 
FE-SZ) was initially performed. Only if this RM-MANOVA re-
vealed a significant effect or a trend of the factor ‘group’ or ‘side 
 ! group’ interaction were separate ANOVAs for the left and right 
hemisphere performed. If appropriate, corrected Tukey’s post hoc 
tests were performed to determine the differences between 
groups.
 Pearson’s product moment correlations between chlorproma-
zine equivalents and dependent variables were calculated for the 
FE-SZ patients.
 Results 
 Sociodemographic and Clinical Characteristics, 
Influence of Intervening Variables Age and Sex on 
Dependent Variables 
 There were no significant age and sex differences be-
tween groups. Schizophrenia patients presented a severe 
degree of illness and severe impairment of social func-
tioning according to Clinical Global Impressions and 
Global Assessment of Functioning and moderate to severe 
positive and negative symptoms (Positive and Negative 
Syndrome Scale). ADHD patients suffered from at least 
moderate symptoms according to the ADHD rating score.
 All schizophrenia patients received an antipsychotic 
medication (but no other concomitant medication, like 
benzodiazepines) and the dosages of daily and cumula-
tive antipsychotic medication (expressed as chlorproma-
zine equivalents) were 356.21  8 203.65 (daily dosage) 
and 7,565.17  8 7,886.79 (cumulative dosage). ADHD pa-
tients and HC were unmedicated. For details of the so-
ciodemographic and clinical characteristics, see  table 1 .
 Except for significant correlations between age and 
RMT (left: r = 0.32, d.f. = 92, p = 0.002; right: r = 0.31,
d.f. = 92, p = 0.003), there was no significant influence
of age on dependent variables. From one-way ANOVA, 
there was no significant difference between female and 
male subjects for any dependent variable.
 Resting Motor Threshold 
 After adjustment for age, no statistically significant 
differences in RMT between groups were revealed ( ta-
ble 2 ).
 Intensity to Evoke MEPs of 1 mV 
 There were no significant differences between groups 
( table 2 ).
Table 1. D emographic and clinical data of study subjects: interval-scaled data are presented as mean 8 standard deviation
Variable FE-SZ ADHD HC Statistic p
Number 25 28 41
Gender (M/F) 18/7 15/13 20/21 2(2) = 3.522 0.17
Age, years 29.9688.5 32.36 8 9.1 33.37 8 9.1 F(2, 91) = 1.140 0.32
Schizophrenia patients
PANSS positive 21.9685.7 – –
PANSS negative 21.7686.4 – –
PANSS general 48.2888.3 – –
PANSS total 92.00814.5 – –
CGI 5.8880.6 – –
GAF 30.0810.5 – –
CPZ1 3568204 – –
CPZ2 7,56587,887 – –
ADHD patients
ADHD-SR total score – 36.7886.3
Attention deficit subscore – 18.2284.6
Subscore impulsivity – 10.6382.1
Subscore hyperactivity – 7.9382.6
V alues are expressed as 2 statistics for categorical variables and F statistics for continuous variables. CGI = Clinical Global Impres-
sion; GAF = Global Assessment of Functioning; CPZ1 = chlorpromazine equivalents, daily dosage; CPZ2 = chlorpromazine equiva-
lents, cumulative dosage; ADHD-SR = ADHD self-rating scale; P = error probability of first kind.
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 Short-Interval Intracortical Inhibition and 
Intracortical Facilitation 
 The RM-MANOVA showed a significant ‘side  ! 
group’ interaction for ICF at 7 ms [F(2, 86) = 6.08, p = 
0.003] and for ICF at 15 ms [F(2, 85) = 5.20, p = 0.007] and 
a trend for the factor ‘group’ for SICI at 3 ms [F(2, 86) = 
3.04, p = 0.053].
 The subsequent ANOVA showed separately for the 
left hemisphere a trend for the factor ‘group’ for SICI at 
3 ms [F(2, 90) = 3.08, p = 0.051, Tukey’s post hoc test: 
trend for FE-SZ  ! HC (p = 0.080)] and a significant effect 
for ICF at 7 ms [F(2, 90) = 4.76, p = 0.011, Tukey’s post 
hoc test: ADHD  1 HC (p = 0.013), ADHD  1 FE-SZ (p = 
0.044)]. ANOVA for the right hemisphere revealed a 
trend for ICF at 15 ms [F(2, 85) = 2.92, p = 0.060, Tukey’s 
post hoc test: trend for ADHD  ! FE-SZ (p = 0.051)] 
( fig. 1 ,  2 ;  table 2 ).
 Contralateral Silent Period 
 For CSP120, RM-MANOVA revealed a significant ef-
fect for the factor ‘group’ [F(2, 47) = 3.84, p = 0.028] and 
a significant ‘side  ! group’ interaction [F(2, 47) = 6.22,
p = 0.004]. For CSP140, RM-MANOVA only showed a 
significant effect for the factor ‘group’ [F(2, 46) = 3.36,
p = 0.043], but no significant ‘side  ! group’ interaction 
[F(2, 46) = 0.17, p = 0.84].
 ANOVA, considered separately for the left and right 
hemisphere, showed a significant effect for the factor 
‘group’ on the left hemisphere for CSP120 [F(2, 67) = 4.61, 
p = 0.013, Tukey’s post hoc tests: ADHD  1 HC (p = 0.028), 
FE-SZ  1 HC (p = 0.042)] ( fig. 3 ) and CSP140 [F(2, 63) = 
3.47, p = 0.037, Tukey’s post hoc tests: FE-SZ  1 HC (p = 
0.032)], but no difference on the right hemisphere for 
CSP120 [F(2, 57) = 0.03, p = 0.97] and CSP140 [F(2, 55) = 
1.22, p = 0.30]. For details, see  table 2 .
 Influence of Antipsychotic Medication on TMS 
Parameters 
 In the group of FE-SZ patients, we did not find a sig-
nificant correlation between antipsychotic medication 
and TMS parameters.
Table 2. M ain outcome parameters
Variable FE-SZ ADHD HC Statistics factor ‘group’ (p values)
RMT left 47.6886.55 50.0486.50 47.4985.93
RMT right 49.0087.43 51.9288.86 48.2988.92 –
S1mV left 57.0889.31 64.79810.57 61.88810.70 –
S1mV right 59.50810.33 64.56813.35 63.65814.48 –
CSP120 left 160.82841.59 164.72833.78 133.64840.88 0.013
CSP120 right 165.04855.03 162.81843.89 166.48837.38 0.974
CSP140 left 203.89842.63 192.45846.53 172.36838.29 0.037
CSP140 right 210.38853.60 197.40857.13 186.34844.19 0.303
SICI 3 ms left 39.61829.97 39.68836.95 23.90817.63 0.051
SICI 3 ms right 51.11857.97 35.70832.54 32.00822.99 0.183
SICI 5 ms left 82.88883.18 90.86851.28 63.86835.86 –
SICI 5 ms right 86.87874.57 74.69850.88 81.48855.73 –
ICF 7 ms left 110.688110.01 143.54879.73 94.35849.14 0.011
ICF 7 ms right 148.238142.51 101.88858.60 113.56867.02 0.400
ICF 15 ms left 162.958131.20 163.578130.08 119.18861.01 0.160
ICF 15 ms right 190.868173.20 107.03867.72 146.68892.61 0.060
FE-SZ: First-episode schizophrenia, ADHD: attention deficit 
hyperactivity disorder; HC: healthy controls; P: error probability 
of first kind; RMT: resting motor threshold (in percent maximum 
stimulator output); S 1mV = intensity to evoke an MEP of 1 mV 
(peak to peak) in percent maximum stimulator output; CSP120 = 
cortical contralateral silent period at 120% RMT (ms); CSP140 = 
cortical contralateral silent period at 140% RMT (ms). SICI: Short-
interval intracortical inhibition at one certain interstimulus in-
terval; ICF: Intracortical facilitation at a defined interstimulus in-
terval. Data are presented as mean 8 standard deviation. Please 
notice that statistical analyses on SICI and ICF values (percent 
MEP amplitude with testpulse alone) were performed on log-
transformed values (raw values are presented in this table). Statis-
tics present results separately for the right and left hemisphere. – = 
RM-MANOVA did not show a side ! group interaction or a 
group effect at least on trend level for this dependent variable, 
therefore no further ANOVAs were performed separately for the 
left and right hemisphere.
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 Discussion 
 Our main results are that both, FE-SZ and ADHD pa-
tients demonstrate a prolonged CSP and a cortical disin-
hibition measured by TMS protocols compared to HC. 
Direct statistical comparison showed that both patient 
groups have a similarly prolonged CSP compared to HC. 
Furthermore, FE-SZ and ADHD patients displayed a 
trend towards a reduced SICI in comparison to HC. A 
generally enhanced ICF was found in ADHD patients in 
the left hemisphere when compared to HC. Apart from 
an enhanced ICF at 15 ms over the right hemisphere and 
reduced ICF at 7 ms over the left hemisphere, TMS mea-
sures in FE-SZ patients did not significantly differ from 
ADHD patients.
 Analysis of hemispheric effects revealed significant 
differences between groups. Both patient groups had a 
significantly different pattern of the hemispheric distri-
bution of the inhibitory CSP and facilitatory ICF com-
pared to HC. Interestingly, despite having a largely similar 
pattern of cortical disinhibition (CSP), a distinct hemi-
spheric distribution of some facilitatory parameters could 
be detected between FE-SZ and ADHD patients ( fig. 2 ).
 The modified cortical excitability in both ADHD and 
FE-SZ patients compared to HC and the divergent hemi-
spheric excitability pattern in both diseases are to our 
knowledge new and important findings that support the 
idea of a common pathological pathway in brain trans-
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 Fig. 1. Relative values for paired-pulse (SICI, ICF) measures on the 
left hemisphere expressed as percentage change compared to the 
test pulse in all groups.  *  p  ! 0.05 (RM-MANOVA),  #  0.05  ^  p  ^  
0.060. At 3 ms, FE-SZ patients (p = 0.080) had a trend towards a 
reduced SICI compared to HC. ADHD patients displayed an en-
hanced ICF at 7 ms compared to HC (p = 0.013) and to FE-SZ
(p = 0.044). The numeric differences for ISI 5 ms and ISI 15 ms 
did not reach significance. Data are presented as mean  8 stan-
dard error of the mean. p values are corrected in accordance to 
Tukey’s test. Analyses were performed on logarithmic trans-
formed data (see Materials and Methods). 
 Fig. 2. Hemispheric differences of ICF at 7 and 15 ms in the FE-SZ 
and ADHD groups. At 7 ms on the left hemisphere, FE-SZ pa-
tients had a reduced ICF compared to ADHD patients (p = 0.044). 
At 15 ms on the right hemisphere, FE-SZ patients had an en-
hanced ICF compared to ADHD patients (p = 0.051). Analyses 
were performed on logarithmic transformed data (see Materials 
and Methods).  *  p  ! 0.05 (RM-MANOVA),  #  0.050  ^  p  ^  0.060. 
 Fig. 3. CSP120 duration on the left hemisphere in all groups. 
ADHD (p = 0.028) and FE-SZ patients (p = 0.042) present a longer 
CSP120 duration compared to HC. ADHD and FE-SZ patients
do not differ concerning the CSP120 duration on the left hemi-
sphere (p = 0.950). Data are presented as mean  8 standard error 
of the mean. p values are corrected in accordance to Tukey’s test.
 *  p  ! 0.05. 
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 1
:4
1:
09
 P
M
 Hasan  /Schneider  /Schneider-Axmann  /
Ruge  /Retz  /Rösler  /Falkai  /Wobrock  
Neuropsychobiology 2013;67:74–8380
mission in these diseases and raise questions about func-
tional brain asymmetry in these diseases. In order to bet-
ter understand the pattern of our result, some hypotheti-
cal and mechanistic explanations are provided below.
 General Remarks 
 The role of SICI and CSP in schizophrenia remains 
controversial. Different studies pointed towards a re-
duced SICI in medicated chronic schizophrenia patients 
 [20, 37, 38] and FE-SZ patients  [11] , whereas other studies 
failed to show this difference  [18, 19] . CSP in medicated 
patients was found to be shortened  [20] or prolonged  [19, 
21, 39, 40] compared to HC. The situation for ADHD is 
more clearly laid out. Two studies revealed a reduced SICI 
in adult ADHD patients  [12, 25] , whereas in another 
study this could not reach statistical significance  [26] . In 
contrast to schizophrenia patients, ADHD patients did 
not show a prolonged CSP compared to HC in previous 
studies  [27] .
 The reduced SICI and the enhanced ICF in FE-SZ and 
ADHD patients in our study can be considered as param-
eters of cortical disinhibition and might be linked to a 
dysfunction of the GABA A neurotransmission. The pro-
longed CSP in both patient groups can be best explained 
by an enhanced GABA B transmission  [14] . To understand 
the relationship of different inhibitory and facilitatory 
pathways, the two following aspects are important.
 Possible Mode of Action with Regard to 
Intrahemispheric and Interhemispheric Networks 
 First, it was shown that CSP and SICI have an inverse 
relationship and that SICI is suppressed and ICF is facili-
tated during CSP. SICI seems to be controlled by presyn-
aptic GABA B receptor-mediated autoinhibition on inhib-
itory GABA A interneurons, similar to a presynaptic au-
toinhibition revealed by paired intracellular recordings 
in slices of rat and human motor cortex  [41, 42] . There-
fore, one explanation of our results might be that the en-
hanced GABA B -related inhibition (CSP) and the reduced 
GABA A -related inhibition (SICI)/enhanced glutamate-
related facilitation (ICF) on the left hemisphere are inter-
dependent and might reflect a compensatory circuit 
within this hemisphere  [21] . However, we are not able to 
determine which network is dysfunctional and which 
network might compensate for this dysfunctionality.
 Second, ADHD and FE-SZ patients presented a modi-
fied hemispheric pattern for CSP and ICF compared to 
HC. This is of particular importance, because abnormal 
brain laterality is a well-known finding in these diseases. 
Especially an atypical lateralization to the right hemi-
sphere explored in EEG and structural MRI studies is an 
important finding in ADHD and schizophrenia  [43–46] . 
It could be hypothesized that this relationship is linked 
to an impaired interhemispheric connectivity/inhibition. 
We did not investigate this in our sample. However, one 
study found an impaired interhemispheric inhibition in 
adult ADHD patients  [27] and a reduced interhemispher-
ic inhibition was observed in schizophrenia patients  [47] .
 But why do FE-SZ patients differ from ADHD patients 
concerning the hemispheric distribution of ICF? We know 
from other studies that a cortical disinhibition of the left 
hemisphere (hyperexcitability) can result in a reduced fa-
cilitation (hypoexcitability) over the contralateral right 
hemisphere  [48–50] . To understand our findings, the cor-
tical disinhibition in both diseases on the left hemisphere 
(enhanced ICF in ADHD, reduced SICI in FE-SZ com-
pared to HC) should be primarily taken into consider-
ation. Therefore, we would like to hypothesize that the 
relatively reduced ICF in ADHD patients on the right 
hemisphere might compensate for the enhanced ICF on 
the left hemisphere. In FE-SZ, this compensatory mecha-
nisms might be impaired and this might be reflected by 
the relatively facilitated ICF on the right hemisphere.
 In general, we would like to discuss an intrahemi-
spheric compensatory mechanism (reflected by CSP en-
hancement), which is unaffected in both patient groups, 
and an interhemispheric compensatory circuit (reflected 
by a reduction of ICF), which seems to be exclusively ac-
tive in the ADHD group.
 Is There a Hypothetical Common Pathophysiological 
Pathway? 
 It is a remarkable finding that FE-SZ and ADHD did 
not differ in our outcome measures, except for the afore-
mentioned difference in ICF in both hemispheres. As hy-
pothesized in the introduction, these diseases might
in part share a common pathophysiological pathway
and one possible pathway could be associated with dys-
functional dopaminergic transmission. Drug studies in 
healthy subjects and research on a hypodopaminergic dis-
ease (Parkinson’s disease) revealed interesting findings 
about the effect of dopamine on TMS parameters. The 
CSP was prolonged after administration of dopamine ag-
onists ( L -DOPA, pergolide) and shortened in patients 
with Parkinson’s disease  [14, 51] . Hence, the prolonged 
duration of the CSP over the left hemisphere might be 
linked with the theory of dopaminergic hyperactivity in 
schizophrenia and ADHD. Here, the enhanced dopami-
nergic input would lead to a compensatory increase of 
GABAergic transmission and probably cause the CSP 
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prolongation  [52] . In ADHD, there is a discussion about 
the possibility of dopaminergic dysbalance in frontal sub-
cortical regions. Recently, we demonstrated an improve-
ment of SICI in ADHD with long-acting methylphenidate 
 [53] . This was interpreted as a dopamine-re lated response 
to the stimulants, possibly reflecting a complex dopami-
nergic-GABAergic interaction. However, with the TMS 
technique we are not able to determine the localization of 
the affected brain regions involved in dopaminergic 
transmission nor directly probe dopaminergic functions. 
Therefore, currently this theory remains speculative.
 Limitations 
 Our comparative study has several limitations. First of 
all, all schizophrenia patients received antipsychotic 
medication, which might have an impact on the results of 
TMS paradigms. We did not find a correlation between 
chlorpromazine equivalents on the results of the TMS 
measures and an influence of antipsychotic drugs on 
TMS measurements is discussed controversially. One re-
cent study showed that unmedicated schizophrenia pa-
tients and patients treated with second-generation anti-
psychotics (risperidone, olanzapine, quetiapine) had a re-
duced CSP and that patients treated with clozapine had 
significantly less SICI and a longer CSP compared to HC 
 [37] . All of our patients received second-generation anti-
psychotic medication but, in contrast to Liu et al.  [37] , 
none of our patients received clozapine. Also, it is impor-
tant to recognize that the schizophrenia patients in our 
study were at their first episode with a relatively short 
treatment history whereas Liu and co-authors investigat-
ed chronically ill schizophrenia patients and patients 
with a schizoaffective disorder. However, reviewing the 
literature, we would expect that antipsychotics should 
compensate for the reduced inhibition and not enhance 
it  [11, 14, 21] . Furthermore, it should be considered that 
the drug-naïve adult ADHD patients showed a motor dis-
inhibition which was not present in HC. Finally, there 
were no significant differences between ADHD and FE-
SZ patients with regard to inhibitory TMS parameters. 
This might support the hypothesis that diminished corti-
cal inhibition is genuine to these diseases. Nevertheless, 
our results in adult ADHD patients are partially in con-
trast with the results of two previous studies, where sig-
nificant differences in SICI and CSP could not be found 
 [26, 27] . This could be due to different methodical proce-
dures in TMS techniques as well as to divergent recruit-
ment strategies. However, our results stay well in line 
with the diminished SICI seen in children and adoles-
cents with ADHD  [22, 54] .
 Although FE-SZ and ADHD patients present a similar 
cortical disinhibition, we cannot rule out that different 
mechanisms may underlie these effects and that these are 
not specifically restricted to these diseases  [55] . Cortical 
disinhibition, as revealed by TMS, might reflect a general 
characteristic of psychiatric conditions, because different 
other psychiatric diseases, like depression or obsessive-
compulsive disorder, are known to show a cortical disin-
hibition  [56, 57] .
 ADHD is a dimensional diagnosis, but diagnosis of 
schizophrenia is based on the qualitative dimensions of 
symptoms. However, they still share some common ex-
ecutive dysfunctions (e.g. working memory, impulsivity) 
and attention deficits, whereas the motor symptoms usu-
ally are opposite. Despite the different subsumed patho-
physiology and phenotypes, a common dopaminergic 
pathway has been discussed in both diseases  [3, 4] . How-
ever, it should be considered that dopamine has a neuro-
modulatory function. The dopamine effect depends on 
spontaneous neuronal activity, dopamine concentration 
and dopaminergic subreceptors  [55] . Therefore, the trans-
fer of our TMS findings to the complex aspects of dopa-
minergic transmission mechanisms to both diseases can 
be done only in a limited manner. Thus, the interpretation 
of our TMS results should be mainly focused on the dis-
cussed primary GABAergic transmission pathways.
 Finally, it should be noted that overlapping parts of 
this study have been published before (see method sec-
tion). However, this is the first study which directly com-
pares cortical excitability in FE-SZ and ADHD. The FE-
SZ resembling abnormal CSP has never been explored in 
ADHD and abnormal late ICF data (15 ms) for FE-SZ 
have never been characterized in previous studies. Fur-
ther, our study reveals TMS-induced functional hemi-
spheric asymmetry for both diagnostic groups. Previous 
papers from our groups provide detailed discussions for 
each diagnostic group with a specific focus on effects of 
one hemisphere  [11, 21, 25] .
 In conclusion, the results of our study provide evi-
dence for a cortical disinhibition in ADHD and FE-SZ 
and for a common pathophysiological pathway. Further-
more, we were able to present a functional hemispheric 
asymmetry in both diseases.
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